Anlon HealthcareNSE:AHCL 17 EBITDA Margin % is 2,839.83% as of Mar. 2026, which is 11933% above its 10-year median of 23.60. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Anlon Healthcare ranks better than 99.79% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anlon Healthcare's EBITDA for the
three
months ended in Mar. 2026 was ₹14,452 Mil. Anlon Healthcare's Revenue for the
three
months ended in Mar. 2026 was ₹509 Mil. Therefore, Anlon Healthcare's EBITDA margin for the quarter that ended in Mar. 2026 was 2,839.83%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anlon Healthcare EBITDA Margin % Related Terms
Anlon Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare (NSE:AHCL) has a EBITDA Margin % of 2,839.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anlon Healthcare and its competitors. This is 11933% above median its historical median of 23.60. Over the past decade, Anlon Healthcare's EBITDA Margin % has ranged from 10.22 to 1,061.15. According to the industry distribution chart, Anlon Healthcare ranks #2 out of 954 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is Anlon Healthcare's EBITDA Margin % too high?
Anlon Healthcare's current EBITDA Margin % of 2,839.83% is 11933% above median its 10-year median of 23.60. Over the past 10 years, this metric has ranged from a low of 10.22 to a high of 1,061.15. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Anlon Healthcare's value of 2,839.83% is 22591.4% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #2 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #2 out of 954 companies for EBITDA Margin %. This places Anlon Healthcare in the top 0% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Anlon Healthcare's value of 2,839.83% is 22591.4% above this benchmark. Historically, Anlon Healthcare's own EBITDA Margin % has ranged from 10.22 to 1,061.15 over the past decade. While the company's 10-year median is 23.60 vs. the industry median of 12.52, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current EBITDA Margin % of 2,839.83% is 22591.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current EBITDA Margin % is 2,839.83%, which is 11933% above median its own 10-year median of 23.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current EBITDA Margin % of 2,839.83%. The current EBITDA Margin % is 2,839.83%, which is 11933% above median its 10-year median of 23.60 and 22591.4% above the Drug Manufacturers industry median of 12.52. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current EBITDA Margin % is 2,839.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
